Recruiting PHASE1 INTERVENTIONAL 1-arm NCT05475210

177Lu-DOTA-EB-TATE in Adult Patients With Advanced, Well- Differentiated Neuroendocrine Tumors

Phase I, Open-Label Study of the Safety and Dosimetry of a 3-Dose Regimen of Escalating Doses of 177Lu-DOTA-EB-TATE in Adult Patients With Advanced, Well- Differentiated Neuroendocrine Tumors

Sponsor: ClinSmart

Conditions Neuroendocrine Tumors

Interventions 177Lu-DOTA-EB-TATE Amino Acid Solution

Updated 5 times since 2022 Last updated: Mar 12, 2024 Started: Jun 18, 2022 Primary completion: Dec 31, 2024 Completion: Mar 30, 2025

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Neuroendocrine Tumors and is currently actively recruiting participants. ClinSmart leads this study, which shows 5 recorded versions since 2022 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Recruiting PHASE1
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE1
Apr 2024 — Jul 2024 [monthly]

Recruiting PHASE1
Sep 2023 — Apr 2024 [monthly]

Recruiting PHASE1
Sep 2022 — Sep 2023 [monthly]

Recruiting PHASE1

First recorded

Jun 2022

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

ClinSmart
Molecular Targeting Technologies, Inc.

Data source: Molecular Targeting Technologies, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• New York, United States